UK's Oyster Tx Rebrands and Raises $60m for Alzheimer's R&D

UK's Oyster Tx rebrands and raises $60m for Alzheimer's R&D

UK start-up Oyster Therapeutics has raised $60m in first-round financing for its novel take on protein degraders, starting with tau in Alzheimer's.

4BIO Capital leads $60M Series A financing of Oyster Therapeutics (formerly Kesmalea Therapeutics) to advance next-generation targeted protein degraders for Alzheimer’s and other neurodegenerative diseases

Proceeds to advance oral, brain-penetrant tau degrader into clinical development as a novel treatment for tau-driven diseases like Alzheimer’sSeries A led by 4BIO Capital with participation from new investors, including Eli Lilly and Company, alongside existing investorsFinancing supports continued development of proprietary SELFTAC® platform for generating small bifunctional targeted protein degraders with enhanced drug-like propertiesEstablish…

London biotech Oyster harvests $60M for tau-targeting brain drugs

Oyster says a tweak it's made to traditional protein degrading technology can help break down tau, which has long been a focus of Alzheimer’s drug research.

Oyster Therapeutics raises $60m for neurological degraders pipeline

London-based life science venture capital fund 4BIO Capital led the investment. New participants in the round included Actium Group, CE Ventures, Eli Lilly, and TOHO Ventures, managed by The post Lilly-backed Oyster Therapeutics raises $60m for neurological degraders appeared first on Pharmaceutical Business review.

Lilly-backed Oyster Therapeutics raises $60m for neurological degraders

Oyster Therapeutics has closed a $60m Series A-2 financing round to advance targeted protein degraders for neurodegenerative diseases including Alzheimer’s.

Oyster Therapeutics raises $60M to bring Alzheimer’s tau degrader to clinic - European Biotechnology Magazine

London-based Kesmalea Therapeutics has raised $60 million (about €53.5 million) in a Series A-2 financing and rebranded as Oyster Therapeutics. The funding will support the development of an oral, brain-penetrant protein degrader targeting tau, a protein implicated in Alzheimer’s disease and other neurodegenerative disorders.